Sangamo Therapeutics Announces First Quarter 2024 Conference Call and Webcast
Sangamo Therapeutics, Inc. (NASDAQ: SGMO) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.
Sangamo Therapeutics to Present Neurology-Focused Pre-Clinical Data From Its Epigenetic Regulation, Capsid Delivery and Genome Engineering Platforms at the 27th Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT) [Yahoo! Finance]
Sangamo Therapeutics to Present Neurology-Focused Pre-Clinical Data From Its Epigenetic Regulation, Capsid Delivery and Genome Engineering Platforms at the 27th Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT)
What You Need To Know About The Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Analyst Downgrade Today [Yahoo! Finance]